Fluidigm

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China

Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that George Mason University in Fairfax, Va., is providing saliva-based COVID-19 testing using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD system.

George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

On Wednesday, February 10, Fluidigm (NASDAQ:FLDM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings Preview: Fluidigm

Researchers Seek Insight into Development and Progression of Multisystem Inflammatory Syndrome in Children

NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients with COVID-19

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company's management will participate in investor meetings at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021.

Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Fluidigm (FLDM) Q4 Earnings Expected to Decline

The stock price of Fluidigm Corporation (NASDAQ: FLDM) increased by 11.2% on Friday, January 22. This is why it happened.

FLDM Stock Price Increased 11.2%: Why It Happened

The company is now cleared to sell its saliva-based COVID-19 test in Europe.

Why Fluidigm Stock Is Flying Higher Today

Seelos Therapeutics

Adamis Pharmaceuticals

BioCryst Pharmaceuticals

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focused on the analysis of single cells and industrial applications of genomics.

Why Fluidigm, Seelos Therapeutics And More Are Moving Today

Fluidigm (FLDM) stock is soaring higher on Friday following an update for the company's saliva-based novel coronavirus test. The post FLDM Stock Alert: Why Fluidigm Shares Are Shooting Higher Today appeared first on InvestorPlace.

FLDM Stock Alert: Why Fluidigm Shares Are Shooting Higher Today

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus. The CE-IVD mark is in conformance with the European Union In Vitro Diagnostic Directive.

Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 10, 2021, after the close of the market.

Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results

Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for  Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Center

New Data Published in Gastroenterology Demonstrate the Power of Fluidigm's Imaging Mass Cytometry on the Hyperion Imaging System to Identify Novel Targets for Pancreatic Cancer Therapy

Inphi

Tenable Holdings Inc

Investors focused on tech growth stocks may want to consider the following businesses, as their quarterly revenue and net income have advanced strongly on a year-over-year basis.

A Trio of Tech Growth Stocks to Consider

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K. Stankovic, MD, PhD, MSPH, to the company's Board of Directors. Dr. Stankovic is a seasoned leader with more than 30 years of research and development experience in academic, government, in vitro diagnostic and device industry settings.

Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: FLDM shares.

NASDAQ: FLDM Investor Notice: Lawsuit against Fluidigm Corporation announced by Shareholders Foundation

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Fluidigm (FLDM).

Looking for a Growth Stock? Why It is Time to Focus on Fluidigm (FLDM)

Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India

Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company's management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, and Wednesday, December 2.

Fluidigm to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Los Angeles, California--(Newsfile Corp. - November 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fluidigm Corporation (NASDAQ: FLDM) ("Fluidigm" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 7, 2019 and November 5, 2019, inclusive (the ''Class...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fluidigm Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - November 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fluidigm Corporation (NASDAQ: FLDM) ("Fluidigm") between February 7, 2019 and November 5, 2019. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Northern District of California. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fluidigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2020 - FLDM

New York, New York--(Newsfile Corp. - November 20, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fluidigm Corporation ("Fluidigm" or "the Company") (NASDAQ: FLDM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Fluidigm securities between February 7, 2019 and November 5, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's...

FLDM Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fluidigm Corporation Investors of Class Action and Lead Plaintiff Deadline: November 20, 2020

New York, New York--(Newsfile Corp. - November 19, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fluidigm Corporation (NASDAQ: FLDM) alleging that the Company violated federal securities laws.Class Period: February 7, 2019 and November 5, 2019Lead Plaintiff Deadline: November 20, 2020Learn more about your recoverable losses in FLDM:

FLDM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 20, 2020 in the Class Action Filed on Behalf of Fluidigm Corporation Limited Shareholders

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fluidigm Corporation ("Fluidigm” or "the Company") (NASDAQ: FLDM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Fluidigm securities between February 7, 2019 and November 5, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/fldm. This clas

FLDM Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fluidigm Corporation Investors of Class Action and Lead Plaintiff Deadline: November 20, 2020

New York, New York--(Newsfile Corp. - November 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February 7, 2019 and November 5, 2019, inclusive (the "Class Period") of the important November 20, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Fluidigm investors under the federal securities laws.To join the Fluidigm class action, go...

FLDM Final Deadline Tomorrow: Rosen, Leading Trial Attorneys, Reminds Fluidigm Corporation Investors of Important November 20 Deadline in Securities Class Action - FLDM

News for Fluidigm Stock (FLDM)